Englewood Cliffs, NJ, May 13, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a development stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that its investigator led study using Psilocybin to treat Parkinson’s disease has been submitted for ethics board review in the Netherlands. Eric Weisblum, CEO of Silo Pharma stated “We are pleased…
